불량한 임신 결과 예측을 위한 임신중기 산모 혈청 inhibin-A 측정의 연관성

키워드

참고문헌 (34)

1. "ACOG educational bulletin. Maternal serum screening. Number 228, September 1996 (replaces no. 154, April 1991). Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists", Int J Gynecol Obstet, 55, pp.299~308 (1996)
2. Dugoff L, "Quad screen as a predictor of adverse pregnancy outcome", Obstet Gynecol, 106, pp.260~267 (2005)
3. Wald NJ, "Prenatal screening for Down’s syndrome using inhibin-A as a serum marker", Prenat Diagn, 16, pp.143~153 (1996)
4. Yaron Y, "Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome", Am J Obstet Gynecol, 181, pp.968~974 (1999)
5. Ilagan JG, "Abnormal multiple marker screens are associated with adverse perinatal outcomes in cases of intrauterine growth restriction", Am J Obstet Gynecol, 191, pp.1465~1469 (2004)
6. Aquilina J, "Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotropin for the prediction of pre-eclampsia", Placenta, 21, pp.487~492 (2000)
7. Jauniaux E, "Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high risk pregnancies", Prenat Diagn, 16, pp.1129~1135 (1996)
8. Lepage N, "Association between second-trimester isolated high maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies", Am J Obstet Gynecol, 188, pp.1354~1359 (2003)
9. Muttukrishna S, "Role of inhibin in normal and high-risk pregnancy", Semin Reprod Med, 22, pp.227~234 (2004)
10. Lockwood GM, "Muttukrishna S. Measurement of inhibin and activin in early human pregnancy: Demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome", Biol Reprod, 57, pp.1490~1494 (1997)
11. 이경훈, "임신주수에 따른 신생아 체중 변화", Obstetrics & Gynecology Science, 44(10), pp.1851~1856 (2001), 대한산부인과학회
12. Simpson JL, "Maternal serum alpha-fetoprotein screening: low and high values for detection of genetic abnormalities", Am J Obstet Gynecol, 155, pp.593~597 (1986)
13. Wald NJ, "First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)", J Med Screen, 10, pp.56~104 (2003)
14. Merkatz IR, "An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities", Am J Obstet Gynecol, 148, pp.886~894 (1984)
15. Bogart MH, "Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities", Prenat Diagn, 7, pp.623~630 (1987)
16. Canick JA, "Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome", Br J Obstet Gynaecol, 95, pp.330~333 (1988)
17. Sorensen TK, "Elevated second trimester human chorionic gonadotropin and subsequent pregnancy induced hypertension", Am J Obstet Gynecol, 169, pp.834~838 (1993)
18. Lieppman RE, "An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome", Am J Obstet Gynecol, 68(6 Pt 1), pp.1852~1857 (1993)
19. Kim SY, "The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down’s syndrome", Yonsei Med J, 41, pp.226~229 (2000)
20. 김현수, "임신성 고혈압의 예측 지표로서 임신중기에 증가된 융모성 성선 자극 호르몬의 임상적 유용성", 대한산부회지, 42, pp.85~89 (1999)
21. 서용수, "전자간증의 발생 시기와 중등도에 따른임신중기 삼중표지검사 수치의 변화", Obstetrics & Gynecology Science, 49(5), pp.1035~1042 (2006), 대한산부인과학회
22. Lambert-Messerlian GM, "Clinical application of inhibin A measeurement: Prenatal serum screening for Down syndrome", Semin Reprod Med, 22, pp.235~242 (2004)
23. Ledger WL, "Measurement of inhibin A and activin A in pregnancy – possible diagnostic applications", Mol Cell Endocrinol, 180, pp.117~121 (2001)
24. Muttukrishna S, "Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia", Human Reprod, 15, pp.1640~1645 (2000)
25. Muttukrishna S, "Activin A and Inhibin A as possible endocrine markers for preeclampsia", Lancet, 349, pp.1285~1288 (1997)
26. Sebire NJ, "Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia", BJOG, 107, pp.795~797 (2000)
27. Petraglia F, "Inhibin, activin and follistatin in the human placenta – a new family of regulatory proteins", Placenta, 18, pp.3~8 (1997)
28. Jauniaux E, "Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies", Am J Pathol, 162, pp.115~125 (2003)
29. Hustin J, "Histological study of the materno-embryonic interface in spontaneous abortion", Placenta, 11, pp.477~486 (1990)
30. Hung TH, "In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies", Am J Pathol, 159, pp.1031~1043 (2001)
31. Florio P, "Preeclampsia with fetal growth restriction: placental and serum activin A and inhibin A levels", Gynecol Endocrinol, 16, pp.365~372 (2002)
32. Silver HM, "Mechanism of increased maternal serum total activin A and inhibin A in preeclampsia", J Soc Gynecol Investig, 9, pp.308~312 (2002)
33. Bersinger NA, "Pregnancy-associated and placental proteins in the placental tissue of normal and preeclamptic women at delivery", Eur J Endocrinol, 147, pp.785~793 (2002)
34. Casagrandi D, "Inhibin, activin, follistatin, activin receptors and betaglycan gene expression in the placental tissue of preeclampsia patients", Mol Hum Reprod, 9, pp.199~203 (2003)

관련 논문AI추천